Retrospective comparative study on the efficacy and toxicity of docetaxel with ramucirumab in patients with advanced or recurrent non small cell lung cancer
Latest Information Update: 14 Feb 2020
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Sep 2019 New trial record
- 01 Sep 2019 Results published in the Anticancer Research